Nov 06, 2025 • Motley Fool
SOMEWHAT-BULLISH
Pulse Biosciences ( PLSE ) Earnings Transcript
Image source: The Motley Fool.Wednesday, November 5, 2025 at 4:30 p.m. ETExecutive Chairman - Paul Arthur LaVioletteContinue reading ...
Nov 05, 2025 • Zacks Commentary
NEUTRAL
Pulse Biosciences, Inc ( PLSE ) Reports Q3 Loss, Lags Revenue Estimates
Pulse Biosciences (PLSE) delivered earnings and revenue surprises of +6.45% and -82.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Oct 13, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Pulse Biosciences Unveils Promising First-in-Human Data for nPulse
PLSE unveils strong first-in-human data for its nPulse Cardiac Surgical System, showcasing safety, speed, and durable AF treatment potential.
Sep 11, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Pulse Biosciences Gets FDA IDE Nod for Atrial Fibrillation Study
PLSE wins FDA IDE approval for its NANOCLAMP AF study, advancing nsPFA tech as a novel option in atrial fibrillation surgery.
Aug 27, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
PLSE Shares Rise on First-in-Human Data for Thyroid Nodule Treatment
Pulse Biosciences shares rise on first-in-human study showing its nsPFA tech cuts thyroid nodule size with strong safety and efficacy.
Aug 13, 2025 • Motley Fool
SOMEWHAT-BULLISH
Pulse Biosciences Cash Jumps in Q2
Pulse Biosciences ( NASDAQ:PLSE ) , a medical device innovator focused on nanosecond pulsed field ablation ( nsPFA ) for treating various conditions, released its second-quarter 2025 results on August 12, 2025. The company reported another pre-commercial quarter, with no revenue.